LOS ANGELES, May 14 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Synvista Therapeutics, Inc. (Amex: SYI). Ross Silver, Director of Research of Vista Partners stated, "Synvista is one of the best small cap investment opportunities investors will come across. The company is conducting four Phase 2 trials in multi-billion dollar markets. Additionally their Hp test which will serve a ~$100M market, could begin to produce revenues as early as next year. It is also important to note that Synvista is led by a top tier management team who has taken compounds from concept to approval, a feat few management teams in small cap biotech have achieved." To view the report on Synvista at no charge, please visit the Vista Partners website at http://www.vistap.com and click on the download research icon located on top right hand corner of the home page.
About Vista Partners:
Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.
About Synvista Therapeutics, Inc.:
Synvista Therapeutics, Inc. is a product-based biotechnology company
engaged in the development of diagnostic tests and drugs to identify and
treat diabetic patients at high risk for the development of cardiovascular
disease. The Company has identified several promising product candidates
that it believes represent novel approaches for diagnosis and treatment in
some of the largest pharmaceutical markets. Currently, Synvista is
advancing the development and commercialization of a diagnostic product and
conducting Phase 2 clinical trials for two of its other drug candidates.
For more information, please visit the Company's website at
Vista Partners LLC
|SOURCE Vista Partners|
Copyright©2008 PR Newswire.
All rights reserved